Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Lupin Limited ( (IN:LUPIN) ).
Lupin Limited has launched Dapagliflozin and Metformin Hydrochloride Extended-Release tablets in the U.S. market, following U.S. FDA approval of its Abbreviated New Drug Application as a bioequivalent version of AstraZeneca’s Xigduo XR. The product will be available in four strengths, broadening Lupin’s U.S. diabetes portfolio and reinforcing its presence in the competitive anti-diabetic segment, a core therapeutic area for the company and a key driver of its global growth strategy.
More about Lupin Limited
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in more than 100 markets. The company focuses on branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients, holding strong positions in India and the U.S. across key therapeutic areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health.
Average Trading Volume: 30,261
Technical Sentiment Signal: Buy
Current Market Cap: 1069.4B INR
For a thorough assessment of LUPIN stock, go to TipRanks’ Stock Analysis page.